The effect of beta-adrenergic stimulation in the expression of the urokinase plasminogen activator receptor in bone marrow mesenchymal stem cells

Nalini, Ronak; Roshandel, Elham; Mohammadzadeh, Samira; Kazemi, Mohammad Hossein; Nikoonezhad, Maryam; Jalili, Arsalan; Hajifathali, Abbas

doi:10.1016/j.genrep.2021.101017

Cited by 3 publications

(2 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Kinase inhibitors (genus kinase inhibitors, roxolitinib, baricitinib, ibrotinib, syk inhibitors and Rho kinase inhibitors), cytokine regulators (IL-2), inhibitors Proteasome (bortzomib, Carfilzomib, Ixazomib), immune and metabolic checkpoint blockade, and Adoptive cell therapy (Tregs, MSCs) are among the second-line treatment options for cGVHD (14,23,(41)(42)(43)(44)(45)(46)(47)(48)(49)(50)(51). Noteworthy, all of the above mentioned drugs are immunosuppressive which increase the risk of serious, severe, and life-threatening infections.…”

Section: Possible Roles Of B Cells In the Development Of Cgvhdmentioning

confidence: 99%

Chronic graft-versus-host disease: focusing on the B cells

Parkhideh¹,

Hajifathali²,

Roshandel³

et al. 2021

PJMHS

View full text Add to dashboard Cite

Graft-versus-host disease (GVHD) has posed many challenges in allogeneic HSCT. Thanks to the development of immunomodulating approaches, the mortality of acute GVHD (aGVHD) is drastically decreased. Nevertheless, chronic GVHD (cGVHD) is became the leading causes of death in patients who survived of aGVHD. Various studies have demonstrated the essential role of B cells in the development of cGVHD. B cells are directly involved in allogeneic reactions through a variety of mechanisms such as alloantibody production, triggering complement system, promoting antibody-dependent cellular cytotoxicity (ADCC), and cross-presentation of immune complexes. It has been known that the pathways involved in the B-cell homeostasis and survival, such as BAFF, BCR, and Notch2 signaling pathways are abnormal in cGVHD. Post-HSCT lymphopenia triggers the continuous release of BAFF, leading to abnormalities in B cell homeostasis, and increasing the survival of alloreactive/autoreactive B cells, leading to production of allo/auto-antibodies. On the other hand, reduction of regulatory B cells following HSCT, causes loss of T cell peripheral tolerance, leading to cGVHD incidence. Therefore, B cells deserve special consideration in allogeneic HSCT, and targeting alloreactive B cells might be a promising approach in cGVHD management. In this article, we discussed the role of B cells in pathophysiology of cGVHD. Keywords: Chronic graft-versus-host disease, Hematopoietic stem cell transplantation, B cell, BAFF

show abstract

Section: Possible Roles Of B Cells In the Development Of Cgvhdmentioning

confidence: 99%

Chronic graft-versus-host disease: focusing on the B cells

Parkhideh¹,

Hajifathali²,

Roshandel³

et al. 2021

PJMHS

View full text Add to dashboard Cite

show abstract

“…By receiving the G‐CSF signal, bone marrow monocytes suppress the osteoblast cells and disrupt the CXCL12‐CXCR4 axis, so HSCs detach from osteoblasts in the endosteal niche and release to peripheral blood. Other factors that involve in HSC mobilization/homing include c‐kit/kit‐ligand, vascular cell adhesion molecule (VCAM)‐1/very late antigen (VLA‐4), urokinase plasminogen activator (uPA)/uPA‐receptor, neutrophil‐derived proteases, and complement system components 13,14 . Neutrophil engraftment is defined as the first day of three consecutive days in which the absolute neutrophil count (ANC) is ≥0.5 × 10 9 /L, whereas platelet engraftment is defined as at least seven consecutive days without platelet transfusion in which the platelet count is >20 × 10 9 /L 15‐17 …”

Section: Introductionmentioning

confidence: 99%

The effect of granulocyte colony‐stimulating factor dose and administration interval after allogeneic hematopoietic cell transplantation on early engraftment of neutrophil and platelet

Noorazar

Bonakchi

Sankanian

et al. 2021

Clinical Laboratory Analysis

Self Cite

View full text Add to dashboard Cite

Background Hematopoietic stem cell transplantation (HSCT) is one of the treatments for hematologic malignancies. Numerous factors affect the HSCT outcome. The purpose of this study was to investigate the effect of post‐HSCT administration of granulocyte colony‐stimulating factor (post‐G‐CSF) on early neutrophil and platelet engraftment in allogeneic HSCT (allo‐HSCT). Material & methods The study was performed on 76 patients diagnosed with AML and ALL. All patients underwent allo‐HSCT at Taleghani stem cell transplantation center, Tehran, Iran, from February 2016 to December 2018. Chemotherapy regimens based on patients' conditions were selected between myeloablative and reduced‐intensity regimens. Results Statistical analysis revealed that the number of administered G‐CSF units after HSCT was a time‐dependent variable. Statistical analysis before day +11 reported that patients who received G‐CSF <14 units had three times better early neutrophil engraftment than those with G‐CSF ≥14 (CI 95%, AHR = 3.03, p:0.002). CD3+ cells count <318.5 × 106/kg was associated with fast platelet engraftment (CI 95%, AHR 2.28, p:0.01). Conclusion In this study, post‐G‐CSF stimulation was associated with early engraftment in a time‐ and dose‐dependent manner. Administration of G‐CSF beyond 14 units resulted in adverse effects on neutrophil early engraftment. It also appeared that with a reduction in CD3+ cell counts, the likelihood of GVHD decreases, and platelet engraftment occurs earlier. Further investigations in the future are required to determine the factors affecting the process of early engraftment.

show abstract